• The number of shares issued has decreased from 29,475,189 to 14,737,594 due to the consolidation of shares at a 2:1 ratio.
  • The consolidation of shares will take place on August 29, 2024.

Planegg/Martinsried, August 26, 2024.  (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced that the 2:1 share capital reduction and consolidation of shares approved by the Annual General Meeting on June 24, 2024 will be implemented as planned.

Following the recent Commercial Register entry and the previous withdrawal of one share, the number of no-par value shares issued will decrease from 29,475,189 to 14,737,594 as a result of the consolidation of shares at a 2:1 ratio, as previously announced. The conversion of shares in the share deposit accounts will happen automatically with a value date (ex-date) of August 29, 2024. The converted Medigene shares will be traded on the stock exchange under the new securities identification number WKN A40ESG (ISIN: DE000A40ESG2) starting August 29, 2024. This change does not impact the Company’s value or affect the individual shareholders’ percentage ownership in Medigene AG.

As an accounting measure, the reduction will result in a reclassification on the liabilities side of Medigene AG’s commercial balance sheet from “subscribed capital” to “capital reserves”. This aims to significantly raise the share’s market value above the nominal value of EUR 1.00 again and, as a precautionary measure, increase Medigene AG’s transaction capability with regard to the minimum issue amount of EUR 1.00 in accordance with Section 9 (1) AktG, without any specific measures currently planned.

For shareholders whose number of shares is not divisible by 2 at the closing on the reference date of August 30, 2024, a so-called “partial rights settlement” is planned. Shareholders can decide individually whether to buy or sell 0.50 Medigene shares in the partial rights settlement. For this purpose, shareholders are expected to receive a letter of instruction prepared accordingly from their depositary bank after September 2, 2024. If shareholders do not provide their depositary bank with a corresponding instruction to round up or round down, the respective fractional portion of shares will be sold automatically, and the proceeds will be credited to the respective shareholders.

—  end of press release  —

About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that are utilized in multiple therapeutic modalities such as T cell receptor engineered T cell (TCR-T) therapies, TCR-guided T cell engager therapies and TCR-natural killer cell therapies for both its in-house product pipeline and partnering.

Medigene’s lead TCR-T program MDG1015 is a potential best-in-class, TCR-T therapy to treat multiple solid tumor indications. The End-to-End Platform technologies enable armoring and enhancing of these T cells to overcome the immunosuppressive tumor microenvironment (TME) and ensure the T cell drug product composition maximizes safety, efficacy and durability of response. Medigene’s MDG1015 is on track for IND filing in Q3 2024 and CTA filing in Q4 2024. For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene AG

Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.